Defendant Name:
Emergent BioSolutions, Inc.
Defendant Type:
Public Company
SIC Code:
2834
CUSIP:
29089Q10
Document Reference:
33-11371
Document Details
Legal Case Name
In the Matter of Emergent BioSolutions, Inc.
Document Name
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Making Findings, and Imposing a Cease-and-Desist Order
Document Date
07-Apr-2025
Document Format
Administrative Proceeding
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On April 7, 2025, the SEC instituted cease-and-desist proceedings against Emergent BioSolutions, Inc., stating: "This proceeding arises out of violations of Section 17(a)(2) of the Securities Act by
Emergent. From at least April 2020 to April 2021 (“relevant period”), Emergent made a series of materially misleading public statements touting Emergent’s ability and readiness to manufacture
COVID-19 vaccine doses at its Bayview facility (“Bayview”) in Baltimore, Maryland, while
omitting information about issues in the state of readiness of its facilities, personnel training, and quality control protocols to implement its contracted manufacturers’ COVID-19 vaccine
manufacturing processes."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Monetary Penalties:
Civil Penalty
Individual:
$1,500,000.00
Shared:
